Octreotide for acromegaly

Expert Review of Endocrinology and Metabolism

Volumn 2, Issue 2, 2007, Pages 129-145

  Cozzi, Renato ^a   Attanasio, Roberto ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Acromegaly; Growth hormone; Insulin like growth factor I; Octreotide; Somatostatin analogue; Tumor size

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TAMOXIFEN;

ABDOMINAL PAIN; ACROMEGALY; AREA UNDER THE CURVE; CHOLELITHIASIS; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; DIARRHEA; DISORDERS OF CARBOHYDRATE METABOLISM; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FLATULENCE; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE SECRETING ADENOMA; HAIR LOSS; HALF LIFE TIME; HORMONE INHIBITION; HUMAN; HYPOPHYSIS ADENOMA; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LIPID METABOLISM; LIVER TOXICITY; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PHARMACODYNAMICS; PREGNANCY; PRENATAL DRUG EXPOSURE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROLACTINOMA; RECEPTOR AFFINITY; REVIEW; SINGLE DRUG DOSE; STEATORRHEA; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSSPHENOIDAL HYPOPHYSECTOMY; TUMOR REGRESSION;

EID: 56249092556     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.2.2.129     Document Type: Review

References (204)

1. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 352, 1455-1461 (1998).
2. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q. J. Med. 39, 1-16 (1970).
3. Giustina A, Barkan A, Casanueva FF et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 85, 526-529 (2000).
4. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q. J. Med. 86, 293-299 (1993).
5. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. (Oxf.) 41, 95-102 (1994).
6. Swearingen B, Barker FG, Katznelson L et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83, 3419-3426 (1998).
7. Biermasz NR, Dekker FW, Pereira AM et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J. Clin. Endocrinol. Metab. 89, 2789-2796 (2004).
8. Holdaway IM, Rajasoorya CR, Gamble GD. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667-674 (2004).
9. Kauppinen-Mäkelin R, Sane T, Reunanen A et al. A Nationwide Survey of Mortality in Acromegaly. J. Clin. Endocrinol. Metab. 90, 4081-4086 (2005).
10. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J. Clin. Endocrinol. Metab. 83, 2646-2652 (1998).
11. Melmed S, Casanueva FF, Cavagnini F et al. Guidelines for acromegaly management. J. Clin. Endocrinol. Metab. 87, 4054-4058 (2002).
12. American Association of Clinical Endocrinologists Acromegaly Guidelines Task Force. Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr. Pract. 10, 213-225 (2004).
13. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin. Endocrinol. (Oxf.) 49, 653-657 (1998).
14. Biermasz NR, van Dulken HV, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J. Clin. Endocrinol. Metab. 85, 4596-4602 (2000).
15. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J. Clin. Endocrinol. Metab. 86, 4072-4077 (2001).
16. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin. Endocrinol. (Oxf.) 58, 86-91 (2003).
17. De P, Rees DA, Davies N et al. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J. Clin. Endocrinol. Metab. 88, 3567-3572 (2003).
18. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur. J. Endocrinol. 152, 379-387 (2005).
19. Barkan AL, Halasz I, Dornfeld KJ et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J. Clin. Endocrinol. Metab. 82, 3187-3191 (1997).
20. Barrande G, Pittino-Lungo M, Coste J et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J. Clin. Endocrinol. Metab. 85, 3779-3785 (2000).
21. Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R. Failure of radiotherapy in acromegaly. Eur. J. Endocrinol. 145, 717-726 (2001).
22. Mestron A, Webb SM, Astorga R et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry. Eur. J. Endocrinol. 151, 439-446 (2004).
23. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 89, 1613-1617 (2004).
24. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J. Clin. Endocrinol. Metab. 90, 800-804 (2005).
25. Attanasio R, Epaminonda P, Motti et al. Gamma-knife radiosurgery in acromegaly: a 4-year-follow-up study. J. Clin. Endocrinol. Metab. 88, 3105-3131 (2003).
26. Castinetti F, Taieb D, Kuhn JM et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J. Clin. Endocrinol. Metab. 90(8), 4483-4488 (2005).
27. Abs R, Verhelst J, Maiter D et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 83(2), 374-8 (1998).
28. Cozzi R, Attanasio R, Barausse M et al. Cabergoline treatment in acromegaly: a renewed role for dopamine agonist? Eur. J. Endocrinol. 139, 516-521 (1998).
29. Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342(16), 1171-1177 (2000).
30. van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295), 1754-1759 (2001).
31. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr. Rev. 16, 427-442 (1995).
32. Bauer W, Briner U, Doepfner W et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 3, 1133-1140 (1982).
33. Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 24(1), 28-47 (2003).
34. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 53, 681-699 (1997).
35. Battershill PE, Clissold SP. Octreotide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 38, 658-702 (1989).
36. Lamberts SWJ, Uitterlinden P, Del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J. Clin. Endocrinol. Metab. 65, 703-710 (1987).
37. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin. Pharmacokinet. 25, 375-391 (1993).
38. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr. Rev. 4, 417-436 (1988).
39. Stalla GK, Brockmeier SJ, Renner U et al. Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur. J. Endocrinol. 130, 125-131 (1994).
40. Benker G, Hackenberg K, Hamburger B, Reinwein D. Effects of growth hormone release-inhibiting hormone and bromocryptine (CB 154) in states of abnormal pituitary adrenal function. Clin. Endocrinol. (Oxf.) 5, 187-190 (1976).
41. Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol. (Copenh.) 120(6), 760-766 (1989).
42. Lancranjan I, Bruns C, Grass C et al. Sandostatin LAR®: pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 44(1 Suppl. 1), 18-26 (1995).
43. Fløgstad AK, Halse J, Haldorsen T et al. Sandostatin LAR in acromegalic patients: a dose-range study. J. Clin. Endocrinol. Metab. 80(12), 3601-3607 (1995).
44. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J. Clin. Endocrinol. Metab. 80, 3267-3272 (1995).
45. Grass P, Marbach P, Bruns C et al. Sandostatin LAR (microencapsulated octreotide acetate) in arromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 45(8 Suppl. 1), 27-30 (1996).
46. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch. Int. Med. 151, 1573-1588 (1991).
47. Ezzat S, Snyder PJ, Young WF et al. Octreotide treatment of acromegaly: a randomized multicenter study. Ann. Int. Med. 117, 711-718 (1992).
48. Newman B, Melmed S, Snyder PJ et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J. Clin. Endocrinol. Metab. 80, 2768-2775 (1995).
49. Cozzi R, Attanasio R, Montini M et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J. Clin. Endocrinol. Metab. 88, 3090-3098 (2003).
50. Cozzi R, Montini M, Attanasio R et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study on its efficacy in the control of disease activity and on tumor shrinkage. J. Clin. Endocrinol. Metab. 91, 1397-1403 (2006).
51. Kaal A, Orskov H, Nielsen S et al. Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment. Eur. J. Endocrinol. 143(3), 353-361 (2000).
52. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J. Clin. Invest. 114(3), 349-356 (2004).
53. Patel SR, Kvols LK, Peterson DA, Gilbertson DT, Moertel CG. Comparison of the pharmacokinetics of octreotide injected at two subcutaneous sites. J. Nat. Cancer Inst. 81, 1926-1929 (1989).
54. Nicholls J, Wynik D, Domin J, Sandler LM, Bloom SR. Pharmacokinetics of the long-acting somastostatin analogue octreotide (SMS 201-995) in acromegaly. Clin. Endocrinol. (Oxf.) 32, 545-550 (1990).
55. Drewe J, Vonderscher J, Hornung K, Munzer J, Rheinardt J, Kissel T. Enhancement of oral absorption of somastostatin analogue. Sandostatin in man. J. Control Rel. 13, 315-316 (1990).
56. Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G. Disposition of Sandostatin, a new synthetic somastostatin analogue, in rats. Drug Metab. Disposit. 17, 699-703 (1989).
57. Kaal A, Frystyk J, Skjaerbaeck C et al. Effects of intramuscular microsphere-encapsulated octreotide on serum growth hormone, insulin-like growth factors (IGFs), free IGFs, and IGF-binding proteins in acromegalic patients. Metabolism 44, 6-14 (1995).
58. Astruc B, Marbach P, Bouterfa H et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J. Clin. Pharmacol. 45(7), 836-844 (2005).
59. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin. Endocrinol. 53, 719-724 (2000).
60. Newman CB. Medical therapy for acromegaly. Endocrinol. Metab. Clin North Am. 28(1), 171-190 (1999).
61. Cozzi R, Attanasio R, Dallabonzana D, Oppizzi G, Liuzzi A, Chiodini PG. Sandostatin sc continuous infusion in acromegaly: a multi-year experience. Proceedings of the meeting "Sandostatin, state of the art", Monte Carlo, France, (1991) (Abstract 17).
62. Roelfsema F, Frolich M, de Boer H, Harris AG. Octreotide treatment in acromegaly: a comparison between pen-treated and pump-treated patients in a cross-over study. Acta Endocrinol. (Kbh) 125, 43-48 (1991).
63. Flogstad AK, Halse J, Bakke S et al. Sandostatin LAR in acromegalic patients: long-term treatment. J. Clin. Endocrinol. Metab. 82, 23-31 (1997).
64. Lancranjan I, Brew Atkinson A; the Sandostatin LAR Group. Results of a European multicentre study with Sandostatin LAR in acromegaly patients. Pituitary 1, 105-114 (1999).
65. Colao A, Ferone D, Marzullo P et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J. Clin. Endocrinol. Metab. 86, 2779-2786 (2001).
66. Bevan JS, Atkin SL, Atkinson AB et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J. Clin. Endocrinol. Metab. 87, 4554-4563 (2002).
67. Amato G, Mazziotti G, Rotondi M et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin. Endocrinol. (Oxf.) 56, 65-71 (2002).
68. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 4465-4473 (2005).
69. Gilbert J, Ketchen M, Kane P et al. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary, 6, 11-18 (2003).
70. Ayuk J, Stewart SE, Stewart PM, Sheppard MC; and the European Sandostatin® LAR® Group. Efficacy of Sandostatin® LAR® (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin. Endocrinol. (Oxf.) 60, 375-381 (2004).
71. Van der Lely AJ, Harris AG, Lamberts SWJ. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin. Endocrinol. (Oxf.) 37, 181-185 (1992).
72. Colao A, Pivonello R, Cappabianca P et al. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin. Endocrinol. (Oxf.) 63 (3), 342-349 (2005).
73. Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN, Van Wyk JJ. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am. J. Med. 69, 571-575 (1980).
74. Helle SI, Omsjo IH, Hughes SC et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin. Endocrinol. (Oxf.) 45, 727-732 (1996).
75. Eden Engström B, Burman P, Karlsson FA. Men with acromegaly need higher doses of octreotide than women. Clin. Endocrinol. (Oxf.) 56, 73-77 (2002).
76. Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Comm 203, 253-259 (1994).
77. Cozzi R, Barausse M, Lodrini S, Lasio G, Attanasio R. Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J. Endocrinol. Invest. 26, 347-352 (2003).
78. Cozzi R, Attanasio R, Oppizzi G et al. Effects of tamoxifen on GH and IGF-I levels in acromegaly. J. Endocrinol. Invest. 20, 445-451 (1997).
79. Attanasio R, Barausse M, Cozzi R. Raloxifene lowers IGF-I levels in acromegalic women. Eur. J. Endocrinol. 148, 443-448 (2003).
80. Cozzi R, Attanasio R, Grottoli S et al. GH and JGF-I levels in acromegalic patients during treatment with somatostatin analogs: should hormonal targets be lowered to assert a good control of the disease? J. Endocrinol. Invest. 27, 1040-1047 (2004).
81. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin. Endocrinol. (Oxf.) 61(2), 224-231 (2004).
82. Biermasz NR, van den Oever NC, Frölich M et al. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin. Endocrinol. (Oxf.) 58, 288-295 (2003).
83. Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J. Clin. Endocrinol. Metab. 68(4), 844-850 (1989).
84. Plockinger U, Bader M, Hopfenmuller W, Saeger W, Quabbe HJ. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to octreotide therapy and do not correlate with tumor histology. Eur. J. Endocrinol. 136(4), 369-376 (1997).
85. Oppizzi G, Cozzi R, Dallabonzana D et al. Scintigraphic imaging of pituitary adenomas: an "in vivo" evaluation of somatostatin receptors. J. Endocrinol. Invest. 21, 512-519 (1998).
86. Ballarè E, Persani L, Lania AG et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J. Clin. Endocrinol. Metab. 86(8), 3809-3814 (2001).
87. Saveanu A, Gunz G, Dufour H, Enjalbert A, Culler MD, Jaquet P. Distribution and functionality of the somatostatin receptor subtypes in acromegaly. J. Endocrinol. Invest. 26(Suppl. 8), 4-7 (2003).
88. Matrone C, Pivonello R, Colao A et al. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 79(3), 142-148 (2004).
89. Park C, Yang I, Woo J et al. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocrinol. 151(2), 227-236 (2004).
90. Spada A, Arosio M, Bochicchio D et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J. Clin. Endocrinol. Metab. 71(6), 1421-1426 (1990).
91. Pieters GFFM, Smals AGH, Kloppenborg PWC. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N. Engl. J. Med. 314, 1390-1392 (1986).
92. Lamberts SW, Uitterlinden P, Schuijff PC, Klijn JC. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical "cure". Clin. Endocrinol. (Oxf.) 29, 411-420 (1988).
93. Colao A, Ferone D, Lastoria S et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab. 81, 2356-2362 (1996).
94. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JAH. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin. Endocrinol. (Oxf.) 62(3), 282-288 (2005).
95. Webb SM, Prieto L, Badia X et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin. Endocrinol. (Oxf.) 57(2), 251-258 (2002).
96. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J. Clin. Endocrinol. Metab. 90(6), 3337-3341 (2005).
97. Trepp R, Everts R, Stettler C et al. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin. Endocrinol. (Oxf.) 63 (1), 103-110 (2005).
98. Biermasz NR, Van Thiel Sw, Pereira AM et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J. Clin. Endocrinol. Metab. 89, 5369-5376 (2004).
99. Biermasz NR, Pereira AM, Smit JVA, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J. Clin. Endocrinol. Metab. 90, 2731-2739 (2005).
100. Lamberts SWJ, Reubi J-C, Krenning EP. The role of somatostatin analogs in the control of tumor growth. Semin. Oncol. 21 (Suppl 13), 61-64 (1994).
101. Ferjoux G, Bousquet C, Cordelier P et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J. Physiol. 94, 205-210 (2000).
102. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol. Endocrinol. 10, 1688-1696 (1996).
103. Buscail L, Este've J-P, Saint-Laurent N et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc. Natl Acad. Sci. USA 92, 1580-1584 (1995).
104. Cordelier P, Este've J-P, Bousquet C et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype SST5. Proc. Natl Acad. Sci. USA 94, 9343-9348 (1997)
105. Garcia de la Torre N, Wass JAH, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin. Endocrinol. (Oxf.) 57, 425-441 (2002).
106. Koizumi M, Onda M, Tanaka N, Seya T, Yamada T, Takahashi Y. Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 65, 200-206 (2002).
107. Thapar K, Kovacs KT, Stefaneanu L et al. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin. Proc. 72, 893-900 (1997).
108. Losa M, Ciccarelli E, Mortini P et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 86, 5194-5200 (2001).
109. Ezzat S, Horvath E, Harris AG, Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J. Clin. Endocrinol. Metab. 79, 113-118 (1994).
110. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13, 220-240 (1992).
111. Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab. 90, 1856-1863 (2005).
112. Stewart PM, Stewart SE, Clark PM, Sheppard MC. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clin. Endocrinol. (Oxf.) 50, 295-299 (1999).
113. Colao A, De Rosa M, Pivonello R et al. Short-term suppression of GH and IGF-I levels improves gonadal function and sperm parameters in men with acromegaly. J. Clin. Endocrinol. Metab. 87(9), 4193-4197 (2002).
114. Zhu LJ, Krempels K, Bardin CW, O'Carroll AM, Mezey E. The localization of messenger Ribonucleic Acids for Somatostatin Receptors 1, 2, and 3 in rat testis. Endocrinology 139, 350-357 (1998).
115. Vasankari T, Kujala U, Taimela S, Torma A, Irjala K, Huhtaniemi I. Effects of a long acting somatostatin analog on pituitary, adrenal, and testicular function during rest and acute exercise: unexpected stimulation of testosterone secretion. J. Clin. Endocrinol. Metab. 80, 3298-3303 (1995).
116. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr. Rev. 25, 102-152 (2004).
117. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr. Rev. 15 (5), 555-573 (1994).
118. Maffei P, Martini C, Milanesi A et al. Late potentials and ventricular arrhythmias in acromegaly. Int. J. Cardiol. 104, 197-203 (2005).
119. Vitale G, Pivonello R, Auriemma RS et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin. Endocrinol. (Oxf.) 63, 470-476 (2005).
120. Minniti G, Moroni C, Jaffrain-Rea ML et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin. Endocrinol. (Oxf.) 55, 307-313 (2001).
121. Colao A, Cuocolo A, Marzullo P et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J. Clin. Endocrinol. Metab. 86(4), 1551-1557 (2001).
122. Manelli F, Desenzani P, Boni E et al. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 2(3), 205-210 (1999).
123. Colao A, Marzullo P, Cuocolo A et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin. Endocrinol. (Oxf.) 58(2), 169-176 (2003).
124. Colao A, Spinelli L, Marzullo P et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J. Clin. Endocrinol. Metab. 88(7), 3196-3201 (2003).
125. Rizza RA, Mandarino LJ, Gerich JE. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31, 663-669 (1982).
126. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 151, 551-557 (2000).
127. Cohen R, Chanson P, Bruckert E, Timsit J, Legrand A, Harris AG et al. Effects of octreotide on lipid metabolism in acromegaly. Horm. Metab. Res. 24, 397-400 (1992).
128. Tan KCB, Pang RWC, Tiu SC, Lam KSL. Effects of treatment with Sandostatin® LAR® on small dense LDL and remnant-like lipoproteins in patients with acromegaly. Clin. Endocrinol. (Oxf.) 59, 558-564 (2003).
129. Pekkarinen T, Partinen M, Pelkonen R, Ivanainen M. Steep apnoea and daytime sleepiness in acromegaly: relationship to endocrinological factors. Clin. Endocrinol. (Oxf.) 27, 649-654 (1987).
130. Dostalova S, Sonka K, Smahel Z, Weiss V, Marek J, Horinek D. Craniofacial abnormalities and their relevance for sleep apnea syndrome aetiopathogenesis in acromegaly. Eur. J. Endocrinol. 144, 491-497 (2001).
131. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann. Intern. Med. 115, 527-532 (1991).
132. Ip MSM, Tan KCB, Peh WCG, Lam KSL. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin. Endocrinol. (Oxf.) 55, 477-483 (2001).
133. Herrmann BL, Wessendorf TE, Ajaj W, Kahlke S, Teschler H, Mann K. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur. J. Endocrinol. 151, 309-315 (2004).
134. Lieberman SA, Bjorkengren AG, Hoffman AR. Rheumatologic and skeletal changes in acromegaly. Endocrinol. Metab. North Am. 21, 615-631 (1992).
135. Colao A, Cannavò S, Marzullo P et al. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur. J. Endocrinol. 148(1), 31-38 (2003).
136. Jenkins PJ, Sohaib SA, Akker S et al. The pathology of median neuropathy in acromegaly. Ann. Intern. Med. 133(3), 197-201 (2000).
137. Melmed S. Acromegaly and cancer: not a problem. J. Clin. Endocrinol. Metab. 86, 2929-2934 (2001).
138. Jenkins PJ, Besser M. Acromegaly and cancer: a problem. J. Clin. Endocrinol. Metab. 86, 2935-2941 (2001).
139. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21, 215-244 (2000).
140. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9, 570-573 (1998).
141. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351, 1393-1996 (1998).
142. Wolk A, Mantzoros CS, Andersson SO et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl Cancer Inst. 90, 911-915 (1998).
143. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563-566 (1998).
144. Ma J, Pollak MN, Giovannucci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl Cancer Inst. 91, 620-625 (1999).
145. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni Jr JF. Acromegaly and gastrointestinal cancer. Cancer 68, 1673-1677 (1991).
146. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE & the United Kingdom Acromegaly Study Group. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J. Clin. Endocrinol. Metab. 83, 2730-2734 (1998).
147. Baris D, Gridley G, Ron E et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13, 395-400 (2002).
148. Terzolo M, Reimondo G, Gasperi M et al. Colonoscopic screening and follow-up in patients with acromegaly: a multicentre study in Italy. J. Clin. Endocrinol. Metab. 90, 84-90 (2005).
149. Tita P, Ambrosio MR, Scollo C et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin. Endocrinol. 63, 161-167 (2005).
150. Gasperi M, Martino E, Manetti L et al. Acromegaly study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multicenter study. J. Endocrinol. Invest. 25, 240-245 (2002).
151. Newman CB, Melmed S, George A et al. Octreotide as primary treatment for acromegaly. J. Clin. Endocrinol. Metab. 83, 3034-3040 (1998).
152. Attanasio R, Baldelli R, Pivonello R et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J. Clin. Endocrinol. Metab. 88, 5258-5265 (2003).
153. Colao A, Pivonello R, Rosato F et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin. Endocrinol. (Oxf.) 64(3), 342-351 (2006).
154. Herman-Bonert V, Seliverstov M, Melmed S. Pregnancy in acromegaly: successful therapeutic outcome. J. Clin. Endocrinol. Metab. 83, 727-731 (1998).
155. Cozzi R, Attanasio R, Barausse M. Pregnancy in acromegaly: a one center experience. Eur. J. Endocrinol. 155, 279-284 (2006).
156. Caron P, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P. Outcome of 43 Pregnancies in Acromegalic Women. Proceedings of 87th Annual Meeting of Endocrine Society, San Diego, USA P3-552 (2005).
157. Caron P, Gerbeau C, Pradayrol L. Maternal-fetal transfer of octreotide. N. Engl. J. Med. 333, 601-602 (1995).
158. Fassnacht M, Capeller B, Arlt W, Steck T, Allolio B. Octreotide LAR treatment throughout pregnancy in an acromegalic woman. Clin. Endocrinol. (Oxf.) 55, 411-415 (2001).
159. Epelbaum J. Multiple somatostatin functions along brain development and aging. J. Endocrinol. Invest. 20, 11 (1997).
160. Caron P, Bennet A, Lorenzini F et al. Normal pregnancy in a woman with nesidioblastosis treated with somatostatin analog octreotide. Proceedings of 87th Annual Meeting of Endocrine Society, CA, USA, P1-385 (1999).
161. Caron P, Buscail L, Beckers A et al. Expression of somatostatin receptor SST4 in human placenta and absence of octreotide effect on human placental growth hormone concentration during pregnancy. J. Clin. Endocrinol. Metab. 82, 3771-3776 (1997).
162. Mozas J, Ocon E, Lopez de la Torre M, Suarez AM, Miranda JA, Herruzo AJ. Successful pregnancy in a woman with acromegaly treated with somatostatin analog (octreoride) prior to surgical resection. Int. J. Gynaecol. Obstetr. 65, 71-73 (1999).
163. Takeuchi K, Funakoshi T, Oomori S, Maruo T. Successful pregnancy in an acromegalic woman treated with octreotide. Obst. Gynec. 93, 848 (1999).
164. Mikhail N. Octreotide treatment of acromegaly during pregnancy. Mayo Clin. Proc. 77, 297-298 (2002).
165. Ben-Shlomo A, Melmed S. Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly. J. Clin. Endocrinol. Metab. 88(3), 963-968 (2003).
166. Spinas GA, Zapf J, Landolt AM, Stuckmann G, Froesch ER. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinol. (Kbh) 114(2), 249-256 (1987).
167. Barkan A, Lloyd RV, Chandler WF et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J. Clin. Endocrinol. Metab. 67, 1040-1048 (1988).
168. Lucas-Morante T, Garcia-Uria J, Estrada J et al. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J. Neurosurg. 81(1), 10-14 (1994).
169. Stevenaert A, Beckers A. Presurgical Octreotide: treatment in
170. Colao A, Ferone D, Cappabianca P et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J. Clin. Endocrinol. Metab. 82, 3308-3314 (1997).
171. Tachibana E, Saito K, Yoshida J. Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas. Neurol. Med. Chir. (Tokyo) 39(7), 496-499 (1999).
172. Wasko R, Ruchala M, Sawicka J, Kotwicka M, Liebert W, Sowinski J. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J. Endocrinol. Invest. 23(1), 12-18 (2000).
173. Zielinski G, Podgorski JK, Koziarski A, Siwik J, Zgliczynski W, Wieliczko W, Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma. Neurol Neurochir. Pol. 35(3), 423-437(2001).
174. Lucas T, Astorga R, Catala M; and The Spanish Multicentre Lanreotide Study Group on Acromegaly. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin. Endocrinol. (Oxf.) 58, 471-481 (2003).
175. Yin J, Su CB, Xu ZQ et al. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery. Chin. Med. Sci. J. 20(1), 23-26 (2005).
176. Losa M, Mortini P, Giovanelli M. Is presurgical treatment with somatostatin analogs necessary in acromegalic patients? J. Endocrinol. Invest. 22(11), 871-873 (1999).
177. Biermasz NR, van Dulken H, Roelfsema F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients premeated with octreotide compared to those in untreated matched controls. J. Clin. Endocrinol. Metab. 84, 3551-3555 (1999).
178. Kristof RA, Stoffel-Wagner B, Klingmuller D, Schramm J. Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir. (Wien) 141(4), 399-405 (1999).
179. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on diffferent subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur. J. Endocrinol. 145(2), 137-145 (2001).
180. Plockinger U, Quabbe HJ. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir. (Wien) 147(5), 485-493 (2005).
181. Petrossians P, Martins LB, Espinoza C et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur. J. Endocrinol. 152(1), 1-7 (2005).
182. Colao AM, Attanasio R, Pivonello R et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 91, 85-92 (2006).
183. Marzullo P, Ferone D, Di Somma C et al. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1, 115-120 (1999).
184. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogs in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol (Oxf.) 61, 209-215 (2004).
185. Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur. J. Endocrinol. 152, 569-574 (2005).
186. Jørgensen JO, Feldt-Rasmussen U, Frystyk J et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab. 90(10) 5627-5631 (2005).
187. Feenstra J, de Herder WW, ten Have SM et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365(9471), 1644-1646 (2005).
188. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin. Endocrinol. (Oxf.) 48, 311-316 (1998).
189. Plockinger U, Dienemann D, Quabbe H-J. Gastrointestinal side effects of octreotide during long-term treatment of acromegaly. J. Clin. Endocrinol. Metab. 71, 1658-1662 (1990).
190. Donangelo I, Rodacki M, Peixoto MC, Vaisman M, Caldas NR, Gadelha MC. Dependency and analgesia related to treatment with subcutaneous octreotide in patients with growth hormone-secreting tumors. Endocr. Pract. 10(2), 107-111 (2004).
191. Breidert M, Pinzer T, Wildbrett J, Bornstein SR, Hanefeld M. Long-term effect of octreotide in acromegaly on insulin resistance. Horm. Metab. Res. 27, 226-230 (1995).
192. Quabbe HJ, Plockinger U. Metabolic aspects of acromegaly and its treatment. Metabolism 45(Suppl. 1), 61-62 (1996).
193. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M. Effects of two diffierent somatostatin analogs on glucose tolerance in acromegaly. J. Endocrinol. Invest. 25, 502-507 (2002).
194. Sheppard MC. Primary medical therapy for acromegaly. Clin. Endocrinol (Oxf.) 58, 387-399 (2003).
195. Ronchi CL, Varca V, Beck-Peccoz P et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J. Clin. Endocrinol. Metab. 91, 121-128 (2006).
196. Baldelli R, Battista C, Leonetti F et al. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment Clin. Endocrinol. 59(4), 492-499 (2003).
197. Moschetta A, Stolk MF, Rehfeld JF et al. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol. Ther. 15, 181-185 (2001).
198. Redfern JS, Fortuner WJI. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am. J. Gastroenterol. 90(7), 1042-1052 (1995).
199. Hofland LJ, van der Hock J, van Koetsveld PM et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J. Clin. Endocrinol. Metab. 89(4), 1577-1585 (2004).
200. van der Hoek J, de Herder WW, Feelders RA et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J. Clin. Endocrinol. Metab. 89, 638-645 (2004).
201. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J. Clin. Endocrinol. Metab. 86(7), 2976-2981 (2001).
202. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J. Endocrinol. Invest. 28(Suppl. 11), 36-42 (2005).
203. Jaquet P, Gunz G, Saveanu A et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur. J. Endocrinol. 153(1), 135-141 (2005).
204. Jaquet P, Gunz G, Saveanu A et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs. universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J. Endocrinol. Invest. 28(Suppl. 11), 21-27 (2005).